1. Introduction {#sec1-ijerph-13-01030}
===============

Hepatitis C virus (HCV) infection is a global public health problem affecting 160 million individuals worldwide \[[@B1-ijerph-13-01030]\]. 15%--25% of HCV infections can be removed in the first six months by immune response, while 75%--85% of them become chronic and finally develop into liver cirrhosis and hepatocellular carcinoma, and part become autoimmune disorders and lymphoma \[[@B2-ijerph-13-01030]\]. Currently the approved therapy for HCV-1 is a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV) for 48 and 24 weeks, respectively \[[@B3-ijerph-13-01030]\]. Success of the treatment is defined as an absence of HCV RNA 24 weeks after the cessation of therapy, and approximately 60%--70% sustained virological response (SVR) occurring in HCV-1 infection \[[@B4-ijerph-13-01030]\].

One of the possible causes of antiviral treatment failure is that viral antigen cannot be effectively recognized by T cells; therefore, the immune response can hardly be stimulated by T cells and this has protective effects \[[@B5-ijerph-13-01030],[@B6-ijerph-13-01030]\]. The human leucocyte antigen (HLA) region encodes multiple genes, which participate in antigen presentation and T cell activation \[[@B7-ijerph-13-01030]\]. This region is in the short arm of chromosome 6 and those genes are divided into three categories. Genes involved in antigen processing and presentation reside on class-I and class-II genomic region, including *TAP*, *LMP*, *HLA-DM*, *HLA-DO* and *tapasin*.

Previous studies have indicated that single nucleotide polymorphisms (SNPs) of HLA classic genes were associated with the pathogenesis of many diseases, such as systemic lupus erythematosus (SLE) and human papillomavirus (HPV) related cervical cancer \[[@B8-ijerph-13-01030],[@B9-ijerph-13-01030],[@B10-ijerph-13-01030]\]. As is well known, *IL28B* is related to antiviral therapy. Studies about hepatitis C in the United States showed that the effectiveness of antiviral treatment for blacks and whites is related to polymorphisms of MHC class-II \[[@B11-ijerph-13-01030]\]. These studies suggested that the polymorphism of MHC molecules, especially the *HLA-DM* and *DO* genes, can be regarded as genetic markers which could assist in the diagnosis, outcome prediction and prognosis.

Antigen processing and presentation gene polymorphisms are speculated to be associated with the susceptibility and outcomes of HCV. Our earlier study discovered that *HLA-DMA* rs1063478-T mutant protects against HCV infection \[[@B12-ijerph-13-01030]\]. Thus, further research on *HLA-DM* genes should be to be conducted to reveal the possible relationships between different *HLA-DM* genotypes and treatment outcomes in the Chinese Han population with chronic hepatitis C (CHC).

2. Materials and Methods {#sec2-ijerph-13-01030}
========================

2.1. Ethics Statement {#sec2dot1-ijerph-13-01030}
---------------------

Written informed consent was obtained from all participants in this study, the investigations were carried out following the rules of the Declaration of Helsinki, and the study protocol was checked by the Institutional Review Committee of Nanjing Medical University (2015-SRFA-105).

2.2. Study Subjects {#sec2dot2-ijerph-13-01030}
-------------------

A total of 336 chronic hepatitis C patients with viral genotype 1 were recruited from the Jurong People's Hospital from January 2011 to May 2015. Eligibility criteria for therapy included: (1) age between 18 and 70 years; (2) treatment-naïve; (3) detectable HCV RNA in serum over a span of more than 6 months of treatment initiation; (4) negative for hepatitis B infection and other types of liver diseases.

All patients were treated for 48 weeks with PEG IFN-α at a dose of 180 μg subcutaneously each week plus daily 600--1000 mg of oral RBV according to the standard guidelines. Successful treatment was identified based on SVR, defined as absence of HCV RNA 24 weeks after the cessation of therapy. In this study, rapid virological response (RVR) were defined as undetectable HCVRNA at 4 weeks of therapy; Early virological response (EVR) were defined as ≥2 log reduction in HCV RNA level compared to baseline HCV RNA level or undetectable HCVRNA at 12 weeks during therapy. Complete early virological response (cEVR) indicated a positive outcome of the treatment of HCV RNA at 4 weeks, but undetectable HCVRNA after 12 weeks' treatment.

2.3. Laboratory Testing {#sec2dot3-ijerph-13-01030}
-----------------------

Blood samples for biochemical analysis, SNP determination, were collected before antiviral therapy. Serum viral load of all treated patients was quantified at baseline, weeks 4, 12, 24, 48, and 24 weeks after cessation of treatment by a Cobas Amplicor HCV Monitor Test (v2.0, Roche, Basel, Switzerland).

2.4. SNP Genotyping {#sec2dot4-ijerph-13-01030}
-------------------

Genomic DNA was extracted from peripheral blood mononuclear cells using protease K digestion and phenol-chloroform purification. The polymorphisms of rs23544, rs3135029, rs1050391 and rs1063478 were genotyped by the TaqMan allelic discrimination assay on ABI PRISM 7900HT Sequence Detection system (Applied Biosystems, San Diego, CA, USA). The primers used for genotyping are listed in [Supplementary Materials Table S1](#app1-ijerph-13-01030){ref-type="app"}. The genotyping results were determined by the allelic discrimination mode of the SDS 2.3 software package (Applied Biosystems, Foster City, CA, USA), and a 100% concordant was achieved.

2.5. Statistical Analysis {#sec2dot5-ijerph-13-01030}
-------------------------

Demographic characteristics of individuals were compared using two-sample *t* tests and chi-square (*χ*^2^) test as appropriate. The association of genotypes with SVR were estimated by odds ratio (OR) and 95% CI using multivariate logistic regression analysis, also adjusted for age, sex, baseline HCV-RNA level, γ-glutamyl transpeptidase (GGT), glucose, T3, T4, platelets, and α-fetal protein (AFP). Cochran-Armitage trend test was used to analyze the combined effect of two independent SNPs (rs23544-G and rs1063478-C). A stepwise regression model was then fit comprised of all variables and subsequently reduced using forwards elimination to analyze predictive factors for SVR. The predictive models of SVR were presented by receiver-operating characteristic (ROC) curve and area under the curve (AUC) represented the prediction value. In all analyses, a *p*-value of 0.05 or less was considered statistically significant. All statistical analyses were performed by Stata/SE (V.12.0 for Windows; StataCorp LP, College Station, TX, USA).

3. Results {#sec3-ijerph-13-01030}
==========

3.1. Baseline Characteristics of the Study Population {#sec3dot1-ijerph-13-01030}
-----------------------------------------------------

Baseline clinical and laboratory indicators of the 336 enrolled patients are shown in [Table 1](#ijerph-13-01030-t001){ref-type="table"}. The RVR, EVR and cEVR rates were 47.3%, 81.6% and 69.5% respectively. A total of 253 patients achieved SVR (75.3%), among them, the mean age was 53.52 ± 8.57 years and 24.9% were males.

Baseline levels of viral load, GGT, glucose, T3, T4, platelets, and AFP were different between the SVR group and the non-SVR group (*p* \< 0.05). Patients with high viral load, T3, T4 and abnormal GGT, glucose, AFP, platelets levels at baseline were more likely to fail in treatment.

3.2. Association of Polymorphisms in HLA-DM with Virological Response to Treatment {#sec3dot2-ijerph-13-01030}
----------------------------------------------------------------------------------

Analysis of allelic frequencies of the investigated polymorphisms showed that both cohorts were in Hardy-Weinberg equilibrium (*p* \> 0.05). Each SNP was analyzed by three genetic models (Dominant, Recessive, and Additive models) to determine the effect on RVR, EVR, cEVR and SVR. All factors were adjusted with a *p-*values \< 0.2 in the univariate analysis.

For patients with the rs23544GG genotype a higher SVR rate (83.3%) was observed in comparison with AG and AA genotypes (71.4% and 56.3% respectively) (Dominant model: OR = 2.04, 95% CI = 1.23--3.35) ([Table 2](#ijerph-13-01030-t002){ref-type="table"}). Similarly, significantly higher SVR rates were observed in subjects with rs1063478TT genotype with respect to those with wild-type genotype or heterozygous genotype (Dominant model: OR = 2.05, 95% CI = 1.24--3.41). Furthermore, rs23544 and rs1063478 was also found to be strongly associated with cEVR (Recessive model: OR = 2.27, 95% CI = 1.02--5.04; Dominant model: OR = 1.70, 95% CI = 1.02--2.82, respectively) ([Supplementary Materials Table S2](#app1-ijerph-13-01030){ref-type="app"}). We also found that patients with rs1063478 TT genotype may be prone to achieve a higher RVR rate (Recessive model: OR = 2.65, 95% CI = 1.16--6.06) ([Supplementary Materials Table S2](#app1-ijerph-13-01030){ref-type="app"}).

Subsequently, we evaluated combined effects by adding up the number of variant alleles of the two SNPs. The results showed that SVR rate increased when patients carrying more favorable rs23544 G and rs1063478 T alleles ([Table 3](#ijerph-13-01030-t003){ref-type="table"}).

3.3. Predictive Factors for SVR {#sec3dot3-ijerph-13-01030}
-------------------------------

As shown in [Table 4](#ijerph-13-01030-t004){ref-type="table"}, a stepwise regression model comprised of all variables was established. Rs23544, rs1063478, baseline glucose, baseline platelet and T4 level were independent predictors of SVR. When including one SNP of rs1063478, a relatively small area was obtained (AUC = 0.587). A bigger AUC of 0.619 was yield when combined with one SNP of rs23544, which suggested that the prediction value of rs23544 was stronger than rs1063478. Adding up the five factors of rs23544, rs1063478, baseline glucose, platelet and T4 level, the prediction value increased to 0.74 ([Figure 1](#ijerph-13-01030-f001){ref-type="fig"}).

4. Discussion {#sec4-ijerph-13-01030}
=============

We selected and analyzed 4SNPs in *HLA-DM* genes, which were related to antigen processing and presentation. The results showed that *HLA-DMB* rs23544 and *HLA-DMA* rs1063478 polymorphism were associated with HCV treatment outcomes. Rs1063478-T and rs23544-G mutants were biomarkers of SVR. *HLA-DMA* rs1063478 (C \> T) makes a missense mutation and *HLA-DMB* rs23544 (A \> G) located in intron region. The two SNPs are both in *HLA-DM* gene and the rs1063478-Tmutation has the potential to alter the function of the encoding protein and influence the role of *DM* gene in antigen processing and presentation. Thus, the mutations may further affect the remove of the virus and influence the achievement of SVR. The combined analysis of the two SNPs indicated that the SVR rate increased when patients carried more favorable rs23544 G and rs1063478 T alleles. The range of confidence interval carrying more than three favorable alleles was relatively wide due to the limited sample size of each group. However, the predictive value of rs1063487-T (AUC = 0.587) was smaller than rs23544-G (AUC = 0.619). According to the stepwise regression analysis, rs23544, rs1063478, baseline glucose, baseline platelet and T4 level were independent predictors of SVR. When including these five factors, the prediction value AUC was 0.74. This predictive model was similar to several previous studies and it could help with the judgment of prognosis and adjustment for therapy regimen \[[@B13-ijerph-13-01030],[@B14-ijerph-13-01030],[@B15-ijerph-13-01030]\].

Sanchez et al. discovered that variation in the *HLA-DM* gene was relevant in producing pathogenicautoantibodies-antiphospholipid antibodies (aPL) in 2004 \[[@B8-ijerph-13-01030]\]. In 2013 Zhang et al. reported the association between *HLA-DM* gene and childhood systemic lupus erythematosus \[[@B16-ijerph-13-01030]\]. Aissani et al. reported that *HLA-DMB* can be a candidate susceptibility gene for HIV-related Kaposi's sarcoma in 2014 \[[@B17-ijerph-13-01030]\]. All these studies proved that the polymorphisms of *HLA-DM* gene are related to diseases of the immune system. Our previous study on HCV susceptibility found that rs1063478 was significant \[[@B12-ijerph-13-01030]\]. Thus, rs1063478 played an important role both in HCV susceptibility and treatment outcomes; also, *HLA-DM* gene was associated with HCV treatment outcomes.

Our treatment cohort had good representativeness because all the patients enrolled in this study were only infected with HCV and from the same district. Besides, a total of 336 patients were included in this study, so the sample size was relatively large, but it has to be pointed out that there are several potential limitations in our study. First, we only genotyped four SNPs in *HLA-DM* gene and only two SNPs were determined. Second, the relationship between the polymorphism of *HLA-DM* gene and treatment outcomes has so far not been explained. It might be associated with different ethnicities. To solve this problem, further studies in racially diverse populations are needed. Last but not least, in the study, only the response to IFN-free regimen has been predicted, but nowadays triple direct antiviral (DAA) therapy is the trend for HCV infection treatment, and an IFN-free regimen, which is at the expense of adverse effects and high costs, has already been widely used in developed countries. In some developing countries, like China, IFN-based therapy is still the first-line therapy for HCV-1 patients \[[@B18-ijerph-13-01030]\]. As a result, researches on IFN-based therapy still have certain significance in Chinese population, and DAA could be a direction of future research.

5. Conclusions {#sec5-ijerph-13-01030}
==============

This study showed that the genetic variants of *HLA-DM* gene may have an important role in treatment response in the Chinese population. Rs23544, rs1063478, baseline glucose, baseline platelet and T4 level were independent predictors of SVR. Rs1063478 located in the missense mutation region and may play an important role in changing the function. Further research should be conducted to elucidate the mechanism of the SNPs.
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###### 

Baseline characteristics of chronic hepatitis C patients treated with IFN/RBV.

  Variables             N-SVR            SVR              *p*-Value
  --------------------- ---------------- ---------------- -----------
  Mean age, years       53.60 ± 8.05     53.52 ± 8.57     0.917
  Age ≥ 50              77 (69.4)        151 (67.1)       0.677
  Male (%)              27 (24.3)        56 (24.9)        0.910
  AST ≥ 40 U/L (%)      61 (54.9)        109 (48.4)       0.262
  ALT ≥ 40 U/L (%)      67 (63.4)        125 (55.6)       0.403
  GGT ≥ 50 (U/L)        50 (45.1)        71 (31.6)        0.015
  GLU \> 6 (mmol/L)     49 (44.1)        58 (25.8)        0.001
  AFP \> 7.02 (ng/mL)   36 (32.4)        45 (20.0)        0.012
  T3 (nmol/L)           1.55 ± 0.44      1.41 ± 0.45      0.008
  T4 (nmol/L)           130.94 ± 33.45   121.55 ± 30.48   0.011
  Anti-TPO ≥ 35 I/mL    16 (14.5)        33 (15.0)        0.913
  baseline HCV-RNA      6.21 ± 0.74      6.00 ± 0.85      0.032
  TP (g/L)              79.79 ± 5.84     78.84 ± 6.80     0.061
  ALB (g/L)             43.34 ± 4.25     43.84 ± 4.29     0.316
  Platelets (10^9^/L)   133.47 ± 68.85   147.48 ± 60.63   0.058
  Abnormal              47 (42.3)        58 (25.9)        0.002
  Normal                64 (57.7)        166 (74.1)       
  WBC (10^9^/L)         4.79 ± 1.79      4.96 ± 1.72      0.394
  Abnormal              43 (39.1)        72 (32.0)        0.199
  Normal                67 (60.9)        153 (68.0)       
  Hemoglobin (g/L)      133.52 ± 17.86   132.94 ± 17.55   0.782
  Abnormal              31 (27.9)        56 (24.9)        0.550
  Normal                80 (72.1)        169 (75.1)       

Abbreviation: IFN, interferon; RBV, ribavirin; N-SVR, non-sustained virological response; SVR, sustained virological response; AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; GLU, glucose; AFP, alpha fetal protein; TP, total protein; ALB, albumin; WBC, white blood cell.

ijerph-13-01030-t002_Table 2

###### 

Association of SNPs in *HLA-DM* with SVR.

  Genotype    N-SVR       SVR          SVR Rate (%)   OR (95% CI)          *p*-Value
  ----------- ----------- ------------ -------------- -------------------- -----------
  rs23544                                                                  
  AA          62 (55.9)   80 (35.6)    56.3           1.00                 \-
  AG          40 (36.0)   100 (44.4)   71.4           1.74 (1.02--2.98)    0.044
  GG          9 (8.1)     45 (20.0)    83.3           3.22 (1.41--7.35)    0.006
  Dominant                                            2.04 (1.23--3.35)    0.005
  Recessive                                           2.52 (1.14--5.58)    0.022
  Additive                                            1.78 (1.23--2.56)    0.002
  rs3135029                                                                
  AA          71 (64.0)   155 (68.9)   68.6           1.00                 \-
  AC          32 (28.8)   63 (28.0)    66.3           1.04 (0.59--1.83)    0.879
  CC          8 (7.2)     7 (3.1)      46.7           0.37 (0.11--1.19)    0.097
  Dominant                                            0.89 (0.53--1.51)    0.686
  Recessive                                           0.36 (0.11--1.17)    0.090
  Additive                                            0.81 (0.52--1.24)    0.337
  rs1050391                                                                
  CC          72 (64.9)   156 (69.3)   68.4           1.00                 \-
  CT          33 (29.7)   62 (27.6)    65.3           0.96 (0.55--1.69)    0.906
  TT          6 (5.4)     7 (3.1)      53.8           0.40 (0.12--1.37)    0.148
  Dominant                                            0.86 (0.51--1.46)    0.577
  Recessive                                           0.41 (0.12--1.37)    0.149
  Additive                                            0.80 (0.52--1.24)    0.331
  rs1063478                                                                
  CC          59 (53.2)   86 (38.2)    59.3           1.00                 \-
  CT          46 (41.4)   111 (49.3)   70.7           1.83 (1.08--3.08)    0.022
  TT          6 (5.4)     28 (12.5)    82.3           4.40 (1.48--13.03)   0.007
  Dominant                                            2.05 (1.24--3.41)    0.005
  Recessive                                           3.15 (1.11--8.96)    0.031
  Additive                                            1.96 (1.29--2.96)    0.002

Logistic regression analyses adjusted for age, gender, gamma-glutamyl transpeptidase, glucose, α-fetal protein, platelets, baseline RNA, T3, T4; Abbreviation: SNP, single nucleotide polymorphism; SVR, sustained virological response; N-SVR, non-sustained virological response; OR, odds ratio; CI, confidence interval; -, reference. Dominant model stands for (homozygous type + hybrid type) vs. wild type; recessive model stands for homozygous type vs. (hybrid type + wild type) and additive model stands for hybrid type vs. homozygous type vs. wild type.
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###### 

Combined effects of rs23544 and rs1063478 with SVR.

  Variables   N-SVR       SVR         SVR Rate (%)   OR (95% CI)            *p*-Value
  ----------- ----------- ----------- -------------- ---------------------- ------------------
  0           28 (25.2)   22 (9.8)    44.0           1.00                   \-
  1           51 (46.0)   94 (41.8)   64.8           2.27 (1.10--4.63)      0.025
  2           31 (27.9)   74 (32.9)   70.5           2.91 (1.37--6.17)      0.005
  3--4        1 (0.9)     35 (15.5)   97.2           45.12 (5.49--370.75)   \<0.001
  Trend                                                                     ^a^ *p* \< 0.001

Variables are numbers of combined favorable mutants (rs23544-G and rs1063478-C); Logistic regression analyses adjusted for age, gender, gamma-glutamyl transpeptidase, glucose, α-fetal protein, platelets, baseline RNA, T3, T4; Abbreviation: SVR, sustained virological response; N-SVR, non-sustained virological response; OR, odds ratio; CI, confidence interval; ^a^ *p*-value was analyzed by Cochran-Armitage trend test.
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###### 

Multivariate Stepwise regression analysis for independent factors of SVR.

  Variables             Coef.    SE      OR (95% CI)         *p*-Value
  --------------------- -------- ------- ------------------- -----------
  rs23544               0.68     0.37    1.98 (1.36--2.89)   \<0.001
  rs1063478             0.79     0.47    2.22 (1.45--3.38)   \<0.001
  GLU                   −0.77    0.12    0.46 (0.27--0.78)   0.004
  Platelets (10^9^/L)   0.70     0.52    2.02 (1.21--3.34)   0.007
  T4                    −0.008   0.004   0.99 (0.98--1.00)   0.046

Abbreviation: SVR, sustained virological response; Coef., coefficient of variation; SE, standard error; OR, odds ratio; CI, confidence interval; GLU, glucose.
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